First Trust Advisors LP raised its stake in shares of Amsurg Corp. (NASDAQ:AMSG) by 823.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,961 shares of the company’s stock after buying an additional 260,328 shares during the period. First Trust Advisors LP owned 0.54% of Amsurg Corp. worth $19,576,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Vaughan Nelson Investment Management L.P. raised its stake in Amsurg Corp. by 54.8% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,949,733 shares of the company’s stock valued at $197,780,000 after buying an additional 1,043,915 shares in the last quarter. Capital Growth Management LP acquired a new stake in Amsurg Corp. during the second quarter valued at about $42,647,000. Bank of Montreal Can acquired a new stake in Amsurg Corp. during the second quarter valued at about $36,148,000. Wells Fargo & Company MN raised its stake in Amsurg Corp. by 20.7% in the third quarter. Wells Fargo & Company MN now owns 1,431,663 shares of the company’s stock valued at $95,993,000 after buying an additional 245,301 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Amsurg Corp. by 55.7% in the second quarter. Ameriprise Financial Inc. now owns 640,142 shares of the company’s stock valued at $49,574,000 after buying an additional 228,973 shares in the last quarter. 98.67% of the stock is owned by institutional investors.
Amsurg Corp. (NASDAQ:AMSG) traded up 0.71% during midday trading on Friday, hitting $66.22. The stock had a trading volume of 296,468 shares. The stock’s 50-day moving average is $64.34 and its 200-day moving average is $70.20. The company has a market capitalization of $3.56 billion, a PE ratio of 20.44 and a beta of 0.67. Amsurg Corp. has a 1-year low of $57.32 and a 1-year high of $86.17.
Amsurg Corp. (NASDAQ:AMSG) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $1.13 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.13. Amsurg Corp. had a return on equity of 8.05% and a net margin of 6.06%. The business earned $822.20 million during the quarter, compared to analyst estimates of $770.29 million. During the same quarter in the prior year, the business posted $1.03 EPS. Amsurg Corp.’s revenue for the quarter was up 26.5% compared to the same quarter last year. Equities research analysts forecast that Amsurg Corp. will post $4.31 EPS for the current year.
Several brokerages have issued reports on AMSG. Citigroup Inc. began coverage on Amsurg Corp. in a research note on Monday, September 26th. They set a “buy” rating and a $79.00 price target for the company. Mizuho lowered Amsurg Corp. from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $95.00 to $71.00 in a research note on Wednesday, November 9th. Wells Fargo & Co. raised Amsurg Corp. from a “market perform” rating to an “outperform” rating in a research note on Wednesday, November 2nd. They noted that the move was a valuation call. KeyCorp reaffirmed a “positive” rating and set a $87.00 price target on shares of Amsurg Corp. in a research note on Tuesday, October 4th. Finally, Zacks Investment Research lowered Amsurg Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Amsurg Corp. currently has an average rating of “Buy” and an average target price of $89.45.
Amsurg Corp. Company Profile